FDA Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
Research from Tufts University, Molecular Cardiology Research Institute has provided new data on adverse drug reactions
March 15th, 2007
Research findings, "Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system)," are discussed in a new report. According to a study from the United States, "Recent national guidelines support combination drug therapy targeting multiple lipid abnormalities. Current drug labeling warns of an increased risk of adverse events with statin and niacin combinations." "These recommendations have been based solely on case reports. We compared the rates of adverse event reports (AERs) received by the United States Food...
Source: FDA Law Weekly (2007-03-15)
|
